Infliximab therapy for moderately severe Crohn's disease and ulcerative colitis: a retrospective comparison over 6 years.

Clin Exp Gastroenterol · 2011 · PMC3108681 · PMID 21694867

Europe PMC DOI

hedged sentence

0.0610

closest p · 1.2× alpha

0.0610

boldest claim

The sentences

marginal significanceP = 0.061so close (0.05 < p ≤ 0.1)

A higher rate of side effects in UC showed only a marginal significance ( P = 0.061).

also in 3,113 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.